Hormone Therapy Boosts Tirzepatide Weight Loss

A Mayo Clinic-led study found that postmenopausal women using menopausal hormone therapy while taking the obesity drug tirzepatide lost approximately 35% more weight than those on tirzepatide alone. The findings, published in The Lancet Obstetrics, Gynaecology, & Women's Health, suggest a potential synergy between hormones and GLP-1-based medications. While the observational study, co-authored by Regina Castaneda and Maria Daniela Hurtado Andrade, cannot prove causation, it highlights a promising new strategy for managing weight gain and cardiometabolic risks after menopause. Outside experts like Gillian Goddard advise caution, emphasizing the need for future randomized clinical trials to confirm these results and explore broader health benefits beyond weight loss. The United States — Food and Drug Administration-approved tirzepatide is a key component of this potential new treatment approach.